In 2017, deal volume in the biopharma space slowed for the third consecutive year. Value in all of the pharma and life sciences sector totaled only about $181 billion, down 23% from a year earlier, according to PricewaterhouseCoopers.

But according to Intec Pharma Ltd. (NTEC) Chief Executive Officer and Vice Chairman Jeffrey Meckler, a slowdown one year doesn't necessarily portend a slowdown the next year. Rather, innovation is often what drives mergers and acquisitions in biopharma.

"Where there's real innovation, there's always someone willing to pay for it," Meckler said.

More from Mergers and Acquisitions

Aceto's Search for Deal May Be Slowed by DOJ Subpoena

Aceto's Search for Deal May Be Slowed by DOJ Subpoena

Could Spotify Be Next on Amazon's Wish List?

Could Spotify Be Next on Amazon's Wish List?

Sprint, T-Mobile Might Have to Do More Than Make Promises to Get Deal Approved

Sprint, T-Mobile Might Have to Do More Than Make Promises to Get Deal Approved

Xerox Received Interest From HPQ Before Fuji Deal: Sources

Xerox Received Interest From HPQ Before Fuji Deal: Sources

Divestitures at Newell Expected in Weeks: Wells Fargo

Divestitures at Newell Expected in Weeks: Wells Fargo